Active, not recruitingPhase 1NCT02567422
Testing the Addition of M6620 (VX-970, Berzosertib) to Usual Chemotherapy and Radiation for Head and Neck Cancer
Studying Cancer of unknown primary site
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Taofeek K Owonikoko, M.DJHU Sidney Kimmel Comprehensive Cancer Center LAO
- Intervention
- Berzosertib(drug)
- Enrollment
- 43 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2026
Study locations (19)
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
- Smilow Cancer Center/Yale-New Haven Hospital, New Haven, Connecticut, United States
- Yale University, New Haven, Connecticut, United States
- Smilow Cancer Hospital Care Center-Trumbull, Trumbull, Connecticut, United States
- Emory University Hospital Midtown, Atlanta, Georgia, United States
- Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
- University of Iowa/Holden Comprehensive Cancer Center, Iowa City, Iowa, United States
- University of Kentucky/Markey Cancer Center, Lexington, Kentucky, United States
- University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
- Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland, United States
- Wayne State University/Karmanos Cancer Institute, Detroit, Michigan, United States
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center, Lebanon, New Hampshire, United States
- Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States
- Case Western Reserve University, Cleveland, Ohio, United States
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02567422 on ClinicalTrials.govOther trials for Cancer of unknown primary site
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07524114Study of High-Precision Evaluation of Molecular ResiduaL Disease Through a PlatfOrm for Cancer TracKing and Interception (SHERLOCK)University Health Network, Toronto
- RECRUITINGNANCT07283939Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment DelaysAlliance for Clinical Trials in Oncology
- RECRUITINGPHASE2NCT06995508Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO TrialRoswell Park Cancer Institute
- RECRUITINGPHASE1NCT06868433TMV Vaccine Therapy Alone and With Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell CancerEmory University
- RECRUITINGPHASE3NCT06589804Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous TreatmentNational Cancer Institute (NCI)
- RECRUITINGNANCT06662058Remote Audiometry to Monitor for Treatment-Related Hearing Loss in Patients With H&N SCC Receiving Cisplatin and/or RadiationEmory University
- RECRUITINGPHASE2NCT06636734Lovastatin and Pembrolizumab for the Treatment of Patients With Recurrent or Metastatic Head and Neck Cancer, LAPP TrialEmory University
- RECRUITINGNANCT06644716[18F]F-FAPI PET-CT to Identify Carcinoma of Unknown Primary OriginErasmus Medical Center